GTx lowers dose in attempt to lift hold on prostate cancer drug
This article was originally published in Scrip
Executive Summary
In an attempt to get the US FDA to lift the clinical hold on the programme evaluating Capesaris (GTx-758) as a first-line hormonal androgen deprivation therapy for advanced prostate cancer and secondary hormonal therapy, GTx said it plans to test the experimental drug at a lower dose – if the agency gives the OK.